Literature DB >> 8261815

Quantitative detection of hepatitis B virus DNA in sera from patients with acute hepatitis B.

N C Tassopoulos1, M C Kuhns, M G Koutelou, A L McNamara, A Todoulos.   

Abstract

Two hundred forty-four serial serum samples from 30 adults hospitalized with benign (nonfulminant) acute hepatitis B were tested for the presence of hepatitis B virus (HBV) DNA by a quantitative solution hybridization assay using a 125I-labeled DNA probe complementary to HBV-DNA sequences. Acute hepatitis B was self-limiting in 28 and progressed to chronicity in the remaining two patients. Of the 28 patients with self-limiting hepatitis, 21 (75%) were hepatitis B e antigen (HBeAg) positive, 26 (93%) were HBV-DNA positive, and one patient (3.6%) was negative for both markers on admission to the hospital. HBV-DNA cleared after HBeAg clearance in 20 (71.4%), before HBeAg clearance in five (17.9%) and simultaneously with the loss of HBeAg in the remaining two (7.1%) of the 27 initially HBV-DNA- and/or HBeAg-positive patients. Moreover, HBV-DNA remained detectable in serum for 13.3 +/- 6.6 (range: 4-22) days after the appearance of anti-HBe in 71.4% of these patients. In contrast, HBV-DNA and HBeAg remained persistently positive in the two patients who developed chronic HBV infection. These data show that (1) viremia frequently persists after disappearance of HBeAg and (2) appearance of anti-HBe does not indicate the cessation of HBV replication in adults with acute self-limiting hepatitis B.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8261815     DOI: 10.1007/bf01299889

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  19 in total

1.  A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group.

Authors:  R P Perrillo; E R Schiff; G L Davis; H C Bodenheimer; K Lindsay; J Payne; J L Dienstag; C O'Brien; C Tamburro; I M Jacobson; R Sampliner; D Feit; J Lefkowitch; M Kuhns; C Meschievitz; B Sanghvi; J Albrecht; A Gibas
Journal:  N Engl J Med       Date:  1990-08-02       Impact factor: 91.245

2.  Search for hepatitis B virus DNA in sera from patients with acute type B or non-A, non-B hepatitis.

Authors:  N C Tassopoulos; G J Papaevangelou; A Roumeliotou-Karayannis; J R Ticehurst; S M Feinstone; R H Purcell
Journal:  J Hepatol       Date:  1986       Impact factor: 25.083

3.  Pattern and duration of HBV DNA seropositivity in acute hepatitis B.

Authors:  J R Wood; H F Taswell; A J Czaja; D Rabe
Journal:  Dig Dis Sci       Date:  1988-04       Impact factor: 3.199

4.  Letter: Infectivity of serum containing HBsAg and antibody to e antigen.

Authors:  K R Berquist; J E Maynard; B L Murphy
Journal:  Lancet       Date:  1976-05-08       Impact factor: 79.321

5.  Studies of HBV replication during acute hepatitis followed by recovery and acute hepatitis progressing to chronic disease.

Authors:  A S Lok; P Karayiannis; T P Jowett; M J Fowler; P Farci; J Monjardino; H C Thomas
Journal:  J Hepatol       Date:  1985       Impact factor: 25.083

6.  Diagnostic value of anti-HBc IgM in high HBV prevalence areas.

Authors:  G Papaevangelou; A Roumeliotou-Karayannis; N Tassopoulos; P Stathopoulou
Journal:  J Med Virol       Date:  1984       Impact factor: 2.327

7.  Type B hepatitis: the infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure.

Authors:  H J Alter; L B Seeff; P M Kaplan; V J McAuliffe; E C Wright; J L Gerin; R H Purcell; P V Holland; H J Zimmerman
Journal:  N Engl J Med       Date:  1976-10-21       Impact factor: 91.245

8.  Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg Vs. anti-HBe positive carriers of hepatitis B virus.

Authors:  S J Hadziyannis; H M Lieberman; G G Karvountzis; D A Shafritz
Journal:  Hepatology       Date:  1983 Sep-Oct       Impact factor: 17.425

9.  Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study.

Authors:  L B Seeff; E C Wright; H J Zimmerman; H J Alter; A A Dietz; B F Felsher; J D Finkelstein; P Garcia-Pont; J L Gerin; H B Greenlee; J Hamilton; P V Holland; P M Kaplan; T Kiernan; R S Koff; C M Leevy; V J McAuliffe; N Nath; R H Purcell; E R Schiff; C C Schwartz; C H Tamburro; Z Vlahcevic; R Zemel; D S Zimmon
Journal:  Ann Intern Med       Date:  1978-03       Impact factor: 25.391

10.  Hepatitis B virus replication in acute hepatitis B, acute hepatitis B virus-hepatitis delta virus coinfection and acute hepatitis delta superinfection.

Authors:  J Genesca; R Jardi; M Buti; L Vives; S Prat; J I Esteban; R Esteban; J Guardia
Journal:  Hepatology       Date:  1987 May-Jun       Impact factor: 17.425

View more
  1 in total

1.  ERS International Congress 2021: highlights from the Respiratory Intensive Care Assembly.

Authors:  Aileen Kharat; Carla Ribeiro; Berrin Er; Christoph Fisser; Daniel López-Padilla; Foteini Chatzivasiloglou; Leo M A Heunks; Maxime Patout; Rebecca F D'Cruz
Journal:  ERJ Open Res       Date:  2022-05-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.